查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844062

下一代癌症诊断市场按产品类型、技术、癌症类型、功能、分期、应用和最终用户划分－2025-2032年全球预测

Next-Generation Cancer Diagnostics Market by Product, Technology, Cancer Type, Function, Staging, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，下一代癌症诊断市场将成长至 715.5 亿美元，复合年增长率为 24.96%。

关键市场统计数据
基准年 2024 120.2亿美元
预计年份：2025年 150.3亿美元
预测年份 2032 715.5亿美元
复合年增长率 (%) 24.96%

定序、多组体学检测和临床分析相结合，开启了整合分子诊断的新时代，这将彻底改变癌症治疗路径。

癌症诊断格局正从单一分析物检测转向整合了分子检测、高通量定序和高级分析技术的综合性、数据丰富的平台。临床医生和研究中心越来越需要能够提供贯穿整个诊疗过程（从风险分层和早期检测到治疗监测）的可操作性资讯的诊断方法。在技​​术小型化、检测灵敏度提高以及生物标记与标靶治疗之间更紧密的转化联繫的推动下，诊断工作流程正在重新设计，以提供更快、更准确的答案，从而指南临床决策。

本导言概述了塑造该行业的几大主题力量，包括湿实验室创新与计算生物学的融合、对互通性和真实世界证据日益增长的期望，以及在不牺牲分析严谨性的前提下加快结果获取速度的日益增长的压力。随着应用范围从专科中心扩展到社区医院和参考实验室，相关人员在平台选择、多组学资料整合和人力投资方面面临复杂的抉择。以下内容整合了这些动态，重点介绍了新的曲折点，并概述了高阶主管和技术领导者必须调整策略以适应不断加速的创新步伐的实际意义。

确定能够加速精准癌症诊断在医疗机构中普及的关键技术、监管和供应链曲折点。

诊断领域的变革正沿着多个相互依存的维度展开。首先，技术的成熟使得以往仅限于研究环境的检测方法得以在临床实验室中应用，并拥有检验的工作流程和品管。其次，分析技术的进步，特别是机器学习和云端基础平台的进步，正在将复杂的分子讯号转化为临床可解读的输出结果，降低了需要清晰、可操作结果的临床医生采用这些方法的门槛。第三，健保和监管体係正在不断发展，以适应伴随诊断和自适应检测模式，使证据生成成为产品开发和上市策略的核心组成部分。

同时，策略采购和生产方式正在重新设计，以减轻近期全球动盪暴露出的供应链脆弱性。相关人员正转向模组化系统和试剂标准化，以降低操作复杂性，同时保持检测性能。诊断开发人员、学术中心和医疗服务提供者之间的合作日益普遍，这体现了一种协作式创新模式，在这种模式下，共同开发和数据共用加速了临床检验。总而言之，这些转变正在创造一种环境，在这个环境中，速度、准确性和互通性将决定哪些技术能够从前景广阔的原型转化为临床常用技术。

评估预计2025年累积关税将如何影响诊断供应链、采购预算和策略性製造选择。

贸易和关税政策环境为诊断公司带来了显着的策略不确定性。已宣布或预计2025年实施的累积关税措施可能会影响整个诊断价值链的成本，尤其会对进口设备、特殊试剂和某些半导体相关组件造成显着影响。此类措施可能会推高实验室设备和耗材的标价，从而加重采购预算压力，并延缓临床环境中的常规升级。

为应对这一局面，各机构正在评估短期策略和中期结构调整。短期策略包括与供应商重新谈判合约、增加关键试剂的缓衝库存以及优化检测流程以降低每次检测的试剂消费量。中期策略方面，製造商和服务提供者可能会加快对区域製造的投资、认证更多契约製造製造商，并重新设计产品架构以最大限度地减少对关税敏感组件的依赖。重要的是，这些调整并非一成不变。监管核准、品质保证流程和资金限制将决定供应链重组的速度。从临床角度来看，实验室应预期价格上涨的压力，但可以透过提高营运效率和优先进行能够显着改善患者预后的高价值检测来减轻下游影响。

透过深入分析多方面的细分方案，将产品类别、技术、临床适应症和最终用户需求结合，从而确定商业化路径的优先顺序。

细緻的细分框架揭示了不同产品类型、技术、癌症适应症、功能用途、分期和最终用户群中，商业机会和营运挑战的交汇点。以产品为基础的生态系包括仪器、试剂和耗材以及软体和服务，其中仪器可进一步细分为分析仪和定序仪。依技术划分，则包括DNA微阵列、实验室晶片、逆转录PCR平台、次世代定序仪、蛋白质微阵列和多重qPCR，每种技术都有不同的灵敏度、通量和资讯学要求，从而影响实验室的工作流程。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合液态生物检体平台，以高灵敏度和特异性早期检测微量残存疾病
  • 引入人工智慧驱动的影像分析以提高肿瘤亚型分类的准确性和预后效果
  • 结合基因组学、蛋白质组学和代谢体学的扩展多体学分析工作流程将实现个人化肿瘤诊断。
  • 新兴的照护现场奈米技术检测方法可用于在资源匮乏的环境中快速现场定量检测癌症生物标记
  • 实施数位双胞胎建模平台，以模拟肿瘤演变并优化个人化治疗策略
  • 伴随诊断测试的发展，针对新出现的罕见癌症突变以及新的标靶治疗，推动了相关疾病的发展。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按产品类型分類的下一代癌症诊断市场

  • 装置
    • 分析器
    • 序列器
  • 试剂和耗材
  • 软体和服务

第九章 按技术分類的下一代癌症诊断市场

  • DNA微阵列
  • 实验室晶片和逆转录PCR
  • 次世代定序
  • 蛋白质微阵列
  • qPCR和多重PCR

第十章 按癌症类型分類的下一代癌症诊断市场

  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 摄护腺癌

第十一章 按功能分類的下一代癌症诊断市场

  • 生物标誌物开发
  • CTC分析
  • 表观遗传分析
  • 基因分析
  • 蛋白质体分析

第十二章 下一代癌症诊断市场（按阶段划分）

  • 早期检测
  • 渐进阶段

第十三章：按应用分類的下一代癌症诊断市场

  • 癌症筛检
  • 伴随诊断
  • 预后
  • 风险评估
  • 治疗监测

第十四章 按最终用户分類的下一代癌症诊断市场

  • 诊断实验室
  • 医院
  • 研究所
    • 学术的
    • 政府

第十五章：按地区分類的下一代癌症诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 下一代癌症诊断市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国下一代癌症诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • Adaptive Biotechnologies Corporation
    • Agena Bioscience, Inc. by Mesa Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Akadeum Life Sciences
    • Almac Group
    • Becton, Dickinson & Company
    • Bio-Techne Corporation
    • Biological Dynamics Inc.
    • bioMerieux SA
    • BioNTech SE
    • Castle Biosciences Inc.
    • Danaher Corporation
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • GE HealthCare
    • Hologic Inc.
    • Illumina, Inc.
    • Johnson & Johnson Services, Inc.
    • Konica Minolta, Inc.
    • Koninklijke Philips NV
    • NeoGenomics Laboratories
    • Novartis AG
    • OPKO Health, Inc.
    • Oxford Nanopore Technologies Limited
    • Perkin Elmer, Inc.
    • Qiagen NV
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Telerad Tech
    • Thermo Fisher Scientific, Inc.
Product Code: MRR-AD36CD898567

The Next-Generation Cancer Diagnostics Market is projected to grow by USD 71.55 billion at a CAGR of 24.96% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.02 billion
Estimated Year [2025] USD 15.03 billion
Forecast Year [2032] USD 71.55 billion
CAGR (%) 24.96%

Framing the era of integrated molecular diagnostics where sequencing, multi-omic assays, and clinical analytics converge to transform cancer care pathways

The landscape of cancer diagnostics is shifting from single-analyte tests toward integrated, data-rich platforms that combine molecular assays, high-throughput sequencing, and advanced analytics. Increasingly, clinicians and research centers demand diagnostics that provide actionable insights across the continuum of care-from risk stratification and early detection to therapeutic monitoring. Driven by technological miniaturization, improvements in assay sensitivity, and stronger translational links between biomarkers and targeted therapies, diagnostic workflows are being reimagined to deliver faster, more precise answers that can guide clinical decision-making.

This introduction frames the broader thematic forces reshaping the industry: convergence of wet-lab innovation with computational biology, heightened expectations for interoperability and real-world evidence, and rising pressure to reduce time-to-result without sacrificing analytical rigor. As adoption expands beyond specialized centers into community hospitals and reference laboratories, stakeholders face complex choices regarding platform selection, integration of multi-omic data, and investment in workforce capabilities. The content that follows synthesizes these dynamics, highlights emergent inflection points, and outlines practical implications for executives and technical leaders who must align strategy with the accelerating pace of innovation.

Identifying the pivotal technological, regulatory, and supply chain inflection points that are accelerating adoption of precision cancer diagnostics across care settings

Transformative shifts in the diagnostics landscape are unfolding along multiple, interdependent axes. First, technological maturation is enabling assays that were once confined to research settings to be deployed in clinical laboratories with validated workflows and quality controls. Second, analytic advances-particularly in machine learning and cloud-based platforms-are converting complex molecular signals into clinically interpretable outputs, thereby lowering the barrier to adoption for clinicians who require clear, actionable results. Third, reimbursement and regulatory ecosystems are evolving to accommodate companion diagnostics and adaptive testing paradigms, making evidence generation a central component of product development and market access strategies.

Concurrently, strategic sourcing and manufacturing approaches are being redesigned to mitigate supply chain vulnerabilities exposed by recent global disruptions. Stakeholders are shifting toward modular systems and reagent standardization to reduce operational complexity while preserving assay performance. Alliances between diagnostic developers, academic centers, and healthcare providers are becoming more common, reflecting a collaborative model of innovation where co-development and data sharing accelerate clinical validation. Taken together, these shifts are creating an environment in which speed, precision, and interoperability determine which technologies transition from promising prototypes to clinical staples.

Assessing how cumulative tariff measures projected in 2025 could reverberate through supply chains, procurement budgets, and strategic manufacturing choices in diagnostics

The policy landscape for trade and tariffs adds an important layer of strategic uncertainty for diagnostic companies, particularly as governments seek to balance domestic industrial priorities with innovation imperatives. Cumulative tariff measures announced or anticipated in 2025 are likely to affect costs across the diagnostic value chain, with pronounced effects on imported instruments, specialty reagents, and certain semiconductor-dependent components. These dynamics can increase the landed cost of equipment and consumables for laboratories, creating pressure on procurement budgets and potentially delaying routine upgrades in clinical settings.

In response, organizations are evaluating near-term tactics and medium-term structural changes. Near-term tactics include renegotiating supplier contracts, increasing buffer inventories for critical reagents, and optimizing assay workflows to reduce per-test reagent consumption. Over the medium term, manufacturers and service providers may accelerate regional manufacturing investments, qualify additional contract manufacturers, and redesign product architectures to minimize exposure to tariff-sensitive parts. Importantly, these adjustments are not deterministic; regulatory approvals, quality assurance processes, and capital constraints will shape the pace at which supply chains can be reconfigured. From a clinical perspective, laboratories should anticipate incremental price pressures but can mitigate downstream impact through operational efficiencies and selective prioritization of high-value assays that demonstrably improve patient outcomes.

Delving into a multifaceted segmentation schema that aligns product classes, technologies, clinical indications, and end-user needs to prioritize commercialization pathways

A nuanced segmentation framework reveals where opportunities and operational challenges converge across product types, technologies, cancer indications, functional applications, staging, and end-users. Based on product, the ecosystem encompasses Instruments, Reagents & Consumables, and Software & Services, with Instruments further differentiated into Analyzers and Sequencers; this distinction clarifies capital investment patterns and recurring revenue dynamics. Based on technology, the landscape spans DNA Microarrays, Lab-on-a-chip and Reverse Transcriptase-PCR platforms, Next-generation Sequencing, Protein Microarrays, and qPCR with Multiplexing capabilities, each bringing distinct sensitivity, throughput, and informatics requirements that shape laboratory workflows.

Based on cancer type, diagnostics are focused across Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer, where differing biomarker architectures and screening paradigms dictate test design and clinical utility studies. Based on function, capabilities range across Biomarker Development, Circulating Tumor Cell analysis, Epigenetic profiling, Genetic analysis, and Proteomic interrogation, which together form integrated pipelines that can enable companion diagnostics and therapeutic monitoring. Based on staging, differentiation between Early Detection and Progressive Staging highlights the divergent performance thresholds and population-level implications of screening versus disease monitoring. Finally, based on application, diagnostic use cases include Cancer Screening, Companion Diagnostics, Prognostics, Risk Assessment, and Therapeutic Monitoring, and end-user settings encompass Diagnostic Laboratories, Hospitals, and Research Institutes-with Research Institutes further categorized into Academic and Governmental entities-each of which demands tailored service models, validation pathways, and commercialization approaches. Synthesizing these segmentation dimensions provides a roadmap for prioritizing product development, clinical validation investments, and go-to-market tactics that align with specific clinical and operational value propositions.

Evaluating regional adoption patterns and commercialization imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform geographic expansion strategies

Regional dynamics will continue to shape adoption trajectories, regulatory approaches, and commercial models for next-generation diagnostics. The Americas demonstrate a strong translational pipeline with significant clinical trial activity and a concentration of reference laboratories that can rapidly adopt advanced platforms, though regional payer landscapes and procurement policies vary across national and subnational boundaries. Europe, Middle East & Africa present a heterogeneous regulatory mosaic where harmonization efforts coexist with country-specific reimbursement frameworks; in these markets, strategic partnerships and local validation studies are often essential to scale adoption. Asia-Pacific features a combination of high-volume public health screening initiatives and rapidly expanding private-sector capabilities, driving demand for both cost-effective assays and high-throughput sequencing solutions.

Across these regions, common themes emerge: the need for robust local evidence generation, the value of interoperability with electronic health records, and the importance of tailored service models that account for laboratory infrastructure and workforce competencies. Companies pursuing geographic expansion should layer regulatory strategy with supply chain resilience and demonstrate clinical utility in region-specific cohorts to accelerate acceptance. Moreover, cross-border collaborations for data sharing and multicenter validation can reduce duplication of effort and speed the translation of promising assays into routine clinical use.

Analyzing evolving competitive dynamics where platform integration, clinical partnerships, and data-driven differentiation define winners in cancer diagnostics

Competitive dynamics in the diagnostics ecosystem are increasingly characterized by platform convergence, strategic collaborations, and a blurring of traditional vendor boundaries. Established instrument manufacturers are integrating software and services to offer end-to-end solutions, while specialized assay developers are partnering with informatics companies to translate complex outputs into clinical decision support. Emerging entrants bring disruptive chemistry or novel miniaturization approaches that challenge incumbent cost structures and open new clinical applications. Across the ecosystem, alliances with academic and clinical institutions remain a key mechanism for clinical validation, enabling faster pathway development and stronger evidence packages to support adoption.

Strategic differentiation is often achieved through a combination of proprietary reagent portfolios, validated workflow integrations, and robust customer support that minimizes laboratory disruption during technology transitions. Companies that invest in scalable cloud architectures, strong data governance, and explainable analytics gain advantage by enabling payers and providers to quantify clinical impact. At the same time, a pragmatic focus on interoperability standards and regulatory readiness reduces friction during market entry. For corporate strategists, balancing short-term commercial wins with long-term investments in platform extensibility and clinical partnerships will determine which organizations lead the next phase of diagnostic innovation.

Practical, high-impact strategic moves for leaders to accelerate adoption, de-risk supply chains, and build durable commercial models in diagnostics

Industry leaders should pursue a coordinated set of actions that align technological capability with pragmatic market realities. First, invest in modular, interoperable platforms that allow incremental capability upgrades without requiring wholesale laboratory retooling; this lowers adoption barriers and preserves customer lifetime value. Second, diversify sourcing strategies by qualifying multiple suppliers for critical reagents and subassemblies and by exploring regional manufacturing alliances to mitigate tariff and logistics risks. Third, embed real-world evidence generation into product roadmaps, designing post-market studies and registries that demonstrate clinical utility and value to payers.

In parallel, prioritize partnerships with healthcare systems and academic centers to co-develop clinical workflows and reimbursement dossiers, and invest in clinician education to accelerate appropriate test utilization. From an operational perspective, adopt lean validation processes and automation to reduce turnaround times while maintaining analytical rigor. Finally, ensure that commercial models are flexible-offering a mix of capital purchase, reagent-as-a-service, and subscription-based software licensing-to match the diverse procurement preferences of hospitals, reference laboratories, and research institutes. These recommendations, taken together, will enhance resilience, accelerate adoption, and maximize clinical impact.

Explaining the layered mixed-methods research approach that combines primary interviews, secondary sources, and transparent validation to underpin strategic insights

The research methodology combines qualitative and quantitative approaches to ensure robust, reproducible insights. Primary research included in-depth interviews with laboratory directors, clinical oncologists, procurement leaders, and technical developers to capture decision drivers, validation requirements, and operational constraints. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, and public clinical trial registries to contextualize technological claims and identify evidence gaps. Data triangulation was employed to cross-validate interview findings with published studies and publicly available regulatory filings.

Analytical processes included thematic coding of qualitative inputs, validation workshops with subject-matter experts, and scenario analysis to assess how policy or supply chain shocks could influence strategic choices. Where applicable, methodological transparency was maintained through documentation of interview protocols, inclusion criteria for literature reviews, and assumptions used in scenario modelling. This layered approach ensures that conclusions are grounded in practitioner experience and corroborated by objective sources, providing a defensible basis for strategic decision-making while acknowledging limitations inherent to evolving technological and policy environments.

Concluding synthesis that integrates technological, commercial, and operational imperatives to guide strategic decision-making in cancer diagnostics

In summary, next-generation cancer diagnostics are at an inflection point where technological maturity, data analytics, and shifting healthcare priorities converge to create novel clinical and commercial opportunities. The transition from isolated assays to integrated platforms will be mediated by regulatory clarity, payer engagement, and the practicalities of laboratory operations. Supply chain stressors and evolving tariff landscapes introduce complexity, but they also create incentives for manufacturers to innovate in product design, regional manufacturing, and service delivery.

For stakeholders across the ecosystem, success will hinge on aligning product development with demonstrable clinical value, investing in interoperable and scalable systems, and forging partnerships that accelerate evidence generation and implementation. By synthesizing segmentation insights, regional dynamics, and competitive trends, this report equips executives with a coherent framework for prioritizing investments and operational changes that translate scientific promise into improved patient outcomes. The path forward is both challenging and navigable, provided organizations adopt disciplined, evidence-centered strategies that anticipate change and adapt rapidly.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of liquid biopsy platforms for early detection of minimal residual disease with high sensitivity and specificity
  • 5.2. Adoption of artificial intelligence-driven image analysis to improve tumor subtyping accuracy and prognostic predictions
  • 5.3. Expansion of multiomics profiling workflows combining genomics proteomics and metabolomics to enable personalized oncology diagnostics
  • 5.4. Emergence of point-of-care nanotechnology assays for rapid on-site quantification of cancer biomarkers in resource-limited settings
  • 5.5. Implementation of digital twin modeling platforms to simulate tumor evolution and optimize individualized treatment strategies
  • 5.6. Growth of companion diagnostic tests targeting emerging rare oncogenic mutations alongside novel targeted therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Cancer Diagnostics Market, by Product

  • 8.1. Instruments
    • 8.1.1. Analyzers
    • 8.1.2. Sequencers
  • 8.2. Reagents & Consumables
  • 8.3. Software & Services

9. Next-Generation Cancer Diagnostics Market, by Technology

  • 9.1. DNA Microarrays
  • 9.2. Lab-on- a- chip & Reverse Transcriptase-PCR
  • 9.3. Next-generation Sequencing
  • 9.4. Protein Microarrays
  • 9.5. qPCR & Multiplexing

10. Next-Generation Cancer Diagnostics Market, by Cancer Type

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Lung Cancer
  • 10.4. Prostate Cancer

11. Next-Generation Cancer Diagnostics Market, by Function

  • 11.1. Biomarker Development
  • 11.2. CTC Analysis
  • 11.3. Epigenetic Analysis
  • 11.4. Genetic Analysis
  • 11.5. Proteomic Analysis

12. Next-Generation Cancer Diagnostics Market, by Staging

  • 12.1. Early Detection
  • 12.2. Progressive Staging

13. Next-Generation Cancer Diagnostics Market, by Application

  • 13.1. Cancer Screening
  • 13.2. Companion Diagnostics
  • 13.3. Prognostics
  • 13.4. Risk Assessment
  • 13.5. Therapeutic Monitoring

14. Next-Generation Cancer Diagnostics Market, by End-User

  • 14.1. Diagnostic Laboratories
  • 14.2. Hospitals
  • 14.3. Research Institutes
    • 14.3.1. Academic
    • 14.3.2. Governmental

15. Next-Generation Cancer Diagnostics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Next-Generation Cancer Diagnostics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Next-Generation Cancer Diagnostics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Abbott Laboratories
    • 18.3.2. Adaptive Biotechnologies Corporation
    • 18.3.3. Agena Bioscience, Inc. by Mesa Laboratories, Inc.
    • 18.3.4. Agilent Technologies, Inc.
    • 18.3.5. Akadeum Life Sciences
    • 18.3.6. Almac Group
    • 18.3.7. Becton, Dickinson & Company
    • 18.3.8. Bio-Techne Corporation
    • 18.3.9. Biological Dynamics Inc.
    • 18.3.10. bioMerieux SA
    • 18.3.11. BioNTech SE
    • 18.3.12. Castle Biosciences Inc.
    • 18.3.13. Danaher Corporation
    • 18.3.14. Exact Sciences Corporation
    • 18.3.15. F. Hoffmann-La Roche Ltd.
    • 18.3.16. GE HealthCare
    • 18.3.17. Hologic Inc.
    • 18.3.18. Illumina, Inc.
    • 18.3.19. Johnson & Johnson Services, Inc.
    • 18.3.20. Konica Minolta, Inc.
    • 18.3.21. Koninklijke Philips N.V.
    • 18.3.22. NeoGenomics Laboratories
    • 18.3.23. Novartis AG
    • 18.3.24. OPKO Health, Inc.
    • 18.3.25. Oxford Nanopore Technologies Limited
    • 18.3.26. Perkin Elmer, Inc.
    • 18.3.27. Qiagen N.V.
    • 18.3.28. Siemens Healthineers AG
    • 18.3.29. Sysmex Corporation
    • 18.3.30. Telerad Tech
    • 18.3.31. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHN